Skip to main content
. Author manuscript; available in PMC: 2022 Jul 13.
Published in final edited form as: Immunity. 2021 Jul 2;54(7):1405–1416.e7. doi: 10.1016/j.immuni.2021.06.001

Table 1.

Summary of the relative Gi signaling and total expression of BILF1 variants

BILF1 variant relative Gi signaling
(GαΔ6qi4myr-IP3, 10 ng DNA/well)
relative expression
(ELISA, 50 ng DNA/well)
wild-type 100% 100%
K122A 16.0 ± 4.5 % (**) 151.3 ± 16.4% (**)
ECL2GGG 63.8 ± 2.8% (**) 25.2 ± 7.3% (**)
ECL2CXCR4a 63.9 ± 6.4% (**) 32.1 ± 2.0% (**)
ECL2CXCR4b 58.5 ± 5.7% (**) 37.3 ± 0.7% (**)
ECL2CxCR4ab 59.5 ± 4.4% (**) 27.1 ± 4.1% (**)
TM6x7-4A 89.1 ± 8.8% (*) 111.1 ± 1.4% (*)
TM6x7-4A1F 78.0 ± 5.1% (**) 108.5 ± 2.7% (ns)
A271F 84.3 ± 13.2% (**) 66.4 ± 13.5% (**)
M240F 112.6 ± 7.5% (*) 92.9 ± 9.0% (ns)
L241F 91.5 ± 2.8% (*) 91.7 ± 9.0% (ns)
Y282A 41.8 ± 4.2% (**) 129.7 ± 7.1% (**)
E121A 55.1 ± 2.0% (**) 58.7 ± 3.2% (**)
H115A 58.1 ± 4.9% (**) 139.4 ± 7.2% (**)
L75A 50.4 ± 10.4% (**) 97.8 ± 7.5% (ns)
NPxxY 59.1 ± 3.8% (**) 84.8 ± 7.8 (*)
CWxM 76.8 ± 3.2% (**) 100.7 ± 4.9% (ns)
CWxP 77.8 ± 3.7% (**) 98.2 ± 10.6% (ns)
SWxP 92.0 ± 8.6% (ns) 90.5 ± 3.6% (ns)
A125F 76.8 ± 0.8% (**) 88.2 ± 3.2% (*)
H288A 98.9 ± 5.7% (ns) 91.5 ± 7.1% (ns)
F286-H288A 87.1 ± 4.2% (**) 85.0 ± 9.3% (*)
H66A-F286A-H288A 76.0 ± 2.3% (**) 79.7 ± 6.1% (**)

ns: not significant

*:

p < 0.05

**:

p < 0.01